Dallas, Texas 03/05/2014 (FINANCIALSTRENDS) – Drug maker CEL-SCI Corporation (NYSEMKT:CVM) announced today that its first U.S located clinical trial site has been commissioned to conduct its phase 3 tests on its cancer drug injection “Multikine* (Leukocyte Interleukin) which is designed to treat head and neck cancer. This trial site is the first to be set up, out of the proposed 10 to 15 testing centres which are planned to be set up across U.S all through 2014. The first test site in U.S is to be based at 21st Century Oncology Research Centre in North Carolina. These tests have been ongoing for the past year outside U.S and covers close to 12 countries across the globe.
The tests for the Multikine* (Leukocyte Interleukin) injection at the Greenville, North Carolina based facility is going to be overseen by Dr. Ron Allison. Laying out the roadmap for the trail in U.S mainland, CEL-SCI Corporation (NYSEMKT:CVM) Chief Executive Officer, Director and Treasurer Geert R. Kersten Esq. has been quoted to have said that, “Our goal is to have between 10 and 15 U.S. clinical centers participating in our Phase III trial. We should be there by this summer.”
The target drug “Multikine” which is a combination of drug compounds Leukocyte and Interleukin and has been designed to be administered to patients in an Injection format has been going through the phase 3 tests for over one year now in centres outside U.S. In the event of the drug getting approved by FDA, the treatment for neck and head cancer would be revolutionized, claims the drug firm. This is because the drug is designed to stimulate the human body’s natural defence mechanism to take on the cancer cells, and there by limit the chances of collateral damage.
The stock of CEL-SCI Corporation (NYSEMKT:CVM) is expected to rally hard on the news of this declaration when markets open today.
